Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPI Trial: [177Lu]Lu-PSMA-617 With or Without Ipilimumab in Very High-risk Prostate Cancer
NCT06388369Phase 2Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in prostate cancer (PCa) (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoints: Feasibility to perform prostatectomy on time and Pathological Complete Response. Started Aug 2025; status: terminated.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06388369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388369.